 |
59 Diseases |  |
24 Trials |
|
24 Trials |  |
1999 News |  |
| «12...14151617181920212223242526» |
- | lacosamide / Generic mfg.
Trial completion: A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects (clinicaltrials.gov) - Aug 1, 2017
P1, N=30, Completed, Sponsor: UCB Biopharma S.P.R.L.
Recruiting --> Completed
- lacosamide / Generic mfg.
Trial primary completion date, Monotherapy: A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures (clinicaltrials.gov) - Aug 1, 2017
P3, N=10, Active, not recruiting, Sponsor: UCB Japan Co. Ltd.
Recruiting --> Completed Trial primary completion date: Jul 2017 --> Sep 2017
- || lacosamide / Generic mfg.
Enrollment closed, Trial primary completion date: VIBES: Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors (clinicaltrials.gov) - Jul 18, 2017
P=N/A, N=93, Active, not recruiting, Sponsor: UCB BIOSCIENCES GmbH
Trial primary completion date: Jul 2017 --> Sep 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Jan 2018
- | Fycompa (perampanel) / Eisai, Catalyst Pharma, Ospolot (sultiam) / AOP Orphan Pharma, Diacomit (stiripentol) / Biocodex, Meiji Seika
Enrollment open: EPIPOP: Population Pharmacokinetics of Antiepileptic in Pediatrics (clinicaltrials.gov) - Jul 4, 2017
P=N/A, N=1000, Recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Jan 2018 Not yet recruiting --> Recruiting
- | lacosamide / Generic mfg.
New P1 trial: A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects (clinicaltrials.gov) - Jul 2, 2017
P1, N=30, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
- | Fycompa (perampanel) / Eisai, Catalyst Pharma, Ospolot (sultiam) / AOP Orphan Pharma, Diacomit (stiripentol) / Biocodex, Meiji Seika
New trial: EPIPOP: Population Pharmacokinetics of Antiepileptic in Pediatrics (clinicaltrials.gov) - Jun 22, 2017
P=N/A, N=1000, Not yet recruiting, Sponsor: Assistance Publique - H
- | lacosamide / Generic mfg.
New P1/2 trial: Open-label Clinical Trial of Lacosamide in ALS (clinicaltrials.gov) - Jun 14, 2017
P1/2, N=30, Not yet recruiting, Sponsor: Chiba University
- lacosamide / Generic mfg.
Trial primary completion date: A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures. (clinicaltrials.gov) - Jun 9, 2017
P2, N=50, Recruiting, Sponsor: UCB Pharma
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> Jun 2018
- |||||| lacosamide / Generic mfg.
Enrollment open: ASPIRE: Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children. (clinicaltrials.gov) - Jun 8, 2017
P2/3, N=75, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Trial primary completion date: Dec 2017 --> Jun 2018 Not yet recruiting --> Recruiting
- ||| lacosamide / Generic mfg.
Enrollment change: An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy (clinicaltrials.gov) - May 11, 2017
P2, N=300, Enrolling by invitation, Sponsor: UCB Pharma
Not yet recruiting --> Recruiting N=192 --> 300
- |||| lacosamide / Generic mfg.
Trial primary completion date: A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures (clinicaltrials.gov) - May 4, 2017
P3, N=500, Enrolling by invitation, Sponsor: UCB BIOSCIENCES, Inc.
N=192 --> 300 Trial primary completion date: Jan 2019 --> Mar 2021
- | lacosamide / Generic mfg.
Trial completion: A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects (clinicaltrials.gov) - Apr 20, 2017
P1, N=24, Completed, Sponsor: UCB Biopharma S.P.R.L.
Trial primary completion date: Jan 2019 --> Mar 2021 Active, not recruiting --> Completed
- | lacosamide / Generic mfg.
New P1 trial: A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects (clinicaltrials.gov) - Mar 22, 2017
P1, N=24, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
- || lacosamide / Generic mfg.
Trial primary completion date: An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy (clinicaltrials.gov) - Mar 13, 2017
P2, N=192, Enrolling by invitation, Sponsor: UCB Pharma
Active, not recruiting --> Completed Trial primary completion date: Jun 2019 --> May 2022
- | lacosamide / Generic mfg.
Trial completion: A Study to Demonstrate the Bioequivalence of Lacosamide Tablets and Dry Syrup in Healthy Male Japanese Subjects (clinicaltrials.gov) - Mar 10, 2017
P1, N=24, Completed, Sponsor: UCB Biopharma S.P.R.L.
Trial primary completion date: Jun 2019 --> May 2022 Recruiting --> Completed
- ||||||| lacosamide / Generic mfg.
Trial completion: Study to Investigate Lacosamide as Add-on Therapy in Subjects ?4 Years to <17 Years of Age With Partial Onset Seizures (clinicaltrials.gov) - Jan 30, 2017
P3, N=404, Completed, Sponsor: UCB Pharma
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| lacosamide / Generic mfg.
Trial initiation date, Trial primary completion date: ASPIRE: Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children. (clinicaltrials.gov) - Jan 13, 2017
P2/3, N=75, Not yet recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Active, not recruiting --> Completed Initiation date: Oct 2016 --> Jul 2017 | Trial primary completion date: May 2026 --> Jun 2020
- ||||||| lacosamide / Generic mfg., carbamazepine / Generic mfg.
Trial completion, Monotherapy: Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older (clinicaltrials.gov) - Jan 12, 2017
P3, N=551, Completed, Sponsor: UCB BIOSCIENCES GmbH
Initiation date: Oct 2016 --> Jul 2017 | Trial primary completion date: May 2026 --> Jun 2020 Active, not recruiting --> Completed
- ||||| lacosamide / Generic mfg.
Enrollment closed, Monotherapy: A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994 (clinicaltrials.gov) - Dec 21, 2016
P3, N=150, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- |||| lacosamide / Generic mfg.
Trial completion, Trial primary completion date: Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy (clinicaltrials.gov) - Dec 5, 2016
P4, N=59, Completed, Sponsor: The Cleveland Clinic
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Nov 2014
- | lacosamide / Generic mfg.
New P1 trial: A Study to Demonstrate the Bioequivalence of Lacosamide Tablets and Dry Syrup in Healthy Male Japanese Subjects (clinicaltrials.gov) - Nov 22, 2016
P1, N=24, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
- | lacosamide / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Lacosamide IV and EEG/EKG (LIVE) Study (clinicaltrials.gov) - Sep 26, 2016
P2, N=72, Terminated, Sponsor: Lawson Health Research Institute
N=90 --> 72 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Aug 2016; Time limitation for recruitment exceeded. 72 of 90 estimated sample recruited.
- lacosamide / Generic mfg.
Enrollment closed, Trial primary completion date: Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy (clinicaltrials.gov) - Aug 29, 2016
P3, N=25, Active, not recruiting, Sponsor: Academisch Ziekenhuis Maastricht
72 of 90 estimated sample recruited. Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Feb 2017
- lacosamide / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: (clinicaltrials.gov) - Aug 26, 2016
P2, N=0, Withdrawn, Sponsor: Indiana University School of Medicine
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Feb 2017 N=50 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Nov 2016 --> Aug 2016
- lacosamide / Generic mfg.
Enrollment closed: Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: (clinicaltrials.gov) - Aug 9, 2016
P2, N=50, Active, not recruiting, Sponsor: Indiana University School of Medicine
N=50 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Nov 2016 --> Aug 2016 Recruiting --> Active, not recruiting
- ||||| lacosamide / Generic mfg.
Enrollment closed: Study to Investigate Lacosamide as Add-on Therapy in Subjects ?4 Years to <17 Years of Age With Partial Onset Seizures (clinicaltrials.gov) - Aug 3, 2016
P3, N=340, Active, not recruiting, Sponsor: UCB Pharma
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| lacosamide / Generic mfg.
Enrollment open, Trial primary completion date: Study to Investigate Lacosamide as Add-on Therapy in Subjects ?4 Years to <17 Years of Age With Partial Onset Seizures (clinicaltrials.gov) - Jun 29, 2016
P3, N=340, Recruiting, Sponsor: UCB Pharma
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | Trial primary completion date: Oct 2016 --> Jan 2017
- || lacosamide / Generic mfg.
Trial primary completion date: VIBES: Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors (clinicaltrials.gov) - Jun 10, 2016
P=N/A, N=100, Recruiting, Sponsor: UCB BIOSCIENCES GmbH
Active, not recruiting --> Recruiting | Trial primary completion date: Oct 2016 --> Jan 2017 Trial primary completion date: Jan 2017 --> Aug 2017
- |||| lacosamide / Generic mfg.
Trial primary completion date: Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures (clinicaltrials.gov) - Jun 10, 2016
P3, N=473, Active, not recruiting, Sponsor: UCB Pharma SA
Trial primary completion date: Jan 2017 --> Aug 2017 Trial primary completion date: Apr 2017 --> Sep 2018
- lacosamide / Generic mfg.
Trial primary completion date: A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures. (clinicaltrials.gov) - Jun 1, 2016
P2, N=50, Recruiting, Sponsor: UCB Pharma
Trial primary completion date: Apr 2017 --> Sep 2018 Trial primary completion date: Mar 2018 --> Dec 2017
- || lacosamide / Generic mfg.
Trial primary completion date: Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy (clinicaltrials.gov) - May 26, 2016
P4, N=55, Active, not recruiting, Sponsor: The Cleveland Clinic
Trial primary completion date: Mar 2018 --> Dec 2017 Trial primary completion date: Jun 2015 --> Dec 2016
- || lacosamide / Generic mfg.
Trial primary completion date: An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy (clinicaltrials.gov) - May 19, 2016
P2, N=192, Enrolling by invitation, Sponsor: UCB Pharma
Trial primary completion date: Jun 2015 --> Dec 2016 Trial primary completion date: Oct 2017 --> Jun 2019
- ||||| lacosamide / Generic mfg.
Enrollment closed: Study to Investigate Lacosamide as Add-on Therapy in Subjects ?4 Years to <17 Years of Age With Partial Onset Seizures (clinicaltrials.gov) - May 16, 2016
P3, N=308, Active, not recruiting, Sponsor: UCB Pharma
Trial primary completion date: Oct 2017 --> Jun 2019 Recruiting --> Active, not recruiting
- |||| lacosamide / Generic mfg., carbamazepine / Generic mfg.
Trial primary completion date, Monotherapy: Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older (clinicaltrials.gov) - May 10, 2016
P3, N=551, Active, not recruiting, Sponsor: UCB BIOSCIENCES GmbH
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Dec 2016
- | lacosamide / Generic mfg.
Trial initiation date, Trial primary completion date: A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures. (clinicaltrials.gov) - Apr 7, 2016
P2, N=50, Recruiting, Sponsor: UCB Pharma
Trial primary completion date: Mar 2016 --> Dec 2016 Trial primary completion date: Jul 2016 --> Mar 2018 | Initiation date: Oct 2013 --> Feb 2014
- lacosamide / Generic mfg., ketamine / Generic mfg., levetiracetam / Generic mfg.
New P3 trial: Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus (clinicaltrials.gov) - Apr 4, 2016
P3, N=40, Active, not recruiting, Sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC
- |||||||||| lacosamide / Generic mfg.
New P2/3 trial: ASPIRE: Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children. (clinicaltrials.gov) - Mar 18, 2016
P2/3, N=75, Not yet recruiting, Sponsor: UCB BIOSCIENCES, Inc.
- |||| lacosamide / Generic mfg.
Trial primary completion date: Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ?1 Month to <4 Years With Partial-onset Seizures (clinicaltrials.gov) - Mar 7, 2016
P3, N=244, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Trial primary completion date: Jul 2016 --> Mar 2018 | Initiation date: Oct 2013 --> Feb 2014 Trial primary completion date: Jul 2018 --> Jul 2019
- |||||| lacosamide / Generic mfg.
Enrollment open, Trial initiation date, Monotherapy: A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994 (clinicaltrials.gov) - Feb 8, 2016
P3, N=150, Enrolling by invitation, Sponsor: UCB Biopharma S.P.R.L.
Trial primary completion date: Jul 2018 --> Jul 2019 Not yet recruiting --> Enrolling by invitation | Initiation date: Feb 2015 --> Jan 2016
- ||||| lacosamide / Generic mfg.
Trial initiation date, Monotherapy: A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994 (clinicaltrials.gov) - Jan 26, 2016
P3, N=150, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
Not yet recruiting --> Enrolling by invitation | Initiation date: Feb 2015 --> Jan 2016 Initiation date: Dec 2015 --> Feb 2015
- lacosamide / Generic mfg.
Trial primary completion date: Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy (clinicaltrials.gov) - Jan 17, 2016
P3, N=25, Recruiting, Sponsor: Academisch Ziekenhuis Maastricht
Initiation date: Dec 2015 --> Feb 2015 Trial primary completion date: Dec 2015 --> Jul 2016
- lacosamide / Generic mfg., phenytoin / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management (clinicaltrials.gov) - Jan 7, 2016
P4, N=3, Terminated, Sponsor: Lawson Health Research Institute
Trial primary completion date: Dec 2015 --> Jul 2016 N=52 --> 3 | Recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Nov 2015; due to slow recruitment and budgetary restraints study was prematurely terminated
- ||| lacosamide / Generic mfg.
Trial completion, HEOR: Effects of Adjunctive Lacosamide on Mood States and Quality of Life (QOL) in Patients With Epilepsy (clinicaltrials.gov) - Dec 25, 2015
P=N/A, N=60, Completed, Sponsor: State University of New York - Downstate Medical Center
N=52 --> 3 | Recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Nov 2015; due to slow recruitment and budgetary restraints study was prematurely terminated Recruiting --> Completed
- |||||||||| lacosamide / Generic mfg.
New P3 trial, Monotherapy: A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994 (clinicaltrials.gov) - Oct 22, 2015
P3, N=150, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
- || lacosamide / Generic mfg.
Trial primary completion date: Lacosamide IV and EEG/EKG (LIVE) Study (clinicaltrials.gov) - Sep 24, 2015
P2, N=90, Recruiting, Sponsor: Lawson Health Research Institute
Recruiting --> Completed Trial primary completion date: Apr 2015 --> Nov 2016
- |||| lacosamide / Generic mfg., fosphenytoin / Generic mfg.
Trial completion: Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures (clinicaltrials.gov) - Sep 3, 2015
P2, N=74, Completed, Sponsor: Aatif Husain
Trial primary completion date: Apr 2015 --> Nov 2016 Active, not recruiting --> Completed
- ||||| lacosamide / Generic mfg., carbamazepine / Generic mfg.
Enrollment closed, Monotherapy: Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older (clinicaltrials.gov) - Aug 28, 2015
P3, N=551, Active, not recruiting, Sponsor: UCB BIOSCIENCES GmbH
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| lacosamide / Generic mfg., carbamazepine / Generic mfg., carbamazepine ER tablet / Generic mfg.
Trial completion, Monotherapy: SP0993: Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older (clinicaltrials.gov) - Aug 27, 2015
P3, N=888, Completed, Sponsor: UCB BIOSCIENCES GmbH
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || lacosamide / Generic mfg.
Trial primary completion date: VIBES: Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=100, Recruiting, Sponsor: UCB BIOSCIENCES GmbH
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Jan 2017
- |||| lacosamide / Generic mfg., carbamazepine / Generic mfg.
Trial primary completion date, Monotherapy: Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older (clinicaltrials.gov) - Aug 13, 2015
P3, N=527, Recruiting, Sponsor: UCB BIOSCIENCES GmbH
Trial primary completion date: May 2016 --> Jan 2017 Trial primary completion date: Jul 2015 --> Mar 2016